METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human tests begin for targeted fatty liver disease drug
Disease control OngoingThis is an early-stage study to check the safety and side effects of a new drug called LY3849891 in people with fatty liver disease (MASLD) who have a specific genetic marker (PNPLA3 I148M). About 176 participants will receive injections of the drug, and researchers will use bloo…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug aims to shrink dangerous liver fat
Disease control OngoingThis study is testing whether an investigational drug called miricorilant can reduce liver fat and improve liver health in adults with NASH/MASH, a serious form of fatty liver disease. About 175 participants will receive either the drug or a placebo for 24 or 48 weeks. The main g…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC